1. Serum microRNA-125b correlates with hepatitis B viral replication and liver necroinflammation 
F. Li, P. Zhou, W. Deng, J. Wang, R. Mao, Y. Zhang, J. Li, J. Yu, F. Yang, Y. Huang, M. Lu, J. Zhang 
Clinical Microbiology and Infection 
Volume 22, Issue 4, Pages 384.e1-384.e10 (April 2016)
DOI: /j.cmi
Copyright © 2016 European Society of Clinical Microbiology and Infectious Diseases Terms and Conditions

2. Fig. 1
Correlations of serum miRNA-125b, miRNA-122, and miRNA-124 with hepatitis B virus (HBV) DNA and hepatitis B surface antigen (HBsAg). (a) Serum miRNA-125b and HBV DNA; (b) serum miRNA-125b and HBsAg; (c) serum miRNA-122 and HBV DNA; (d) serum miRNA-122 and HBsAg; (e) serum miRNA-124 and HBV DNA; (f) serum miRNA-124 and HBsAg.
Clinical Microbiology and Infection  , 384.e1-384.e10DOI: ( /j.cmi )
Copyright © 2016 European Society of Clinical Microbiology and Infectious Diseases Terms and Conditions

3. Fig. 2
Correlations of serum miRNA-125b with liver necroinflammation and fibrosis. (a) Serum miRNA-125b levels in patients with hepatitis B virus (HBV) infection and healthy controls. (b) Distribution of serum miRNA-125b levels in patients at different phases of the course of chronic hepatitis B (CHB) infection. (c, d) Patients were divided into groups by grading of necroinflammation or staging of fibrosis or both. Abbreviations: miRNA, microRNA; HBV, hepatitis B virus; HC, healthy control; IT, immune-tolerant; IR, immune-reactive; IC, inactive carrier; ENH, hepatitis B e antigen negative chronic hepatitis B; G, grading of necroinflammation; S, staging of fibrosis; n, number.
Clinical Microbiology and Infection  , 384.e1-384.e10DOI: ( /j.cmi )
Copyright © 2016 European Society of Clinical Microbiology and Infectious Diseases Terms and Conditions

4. Fig. 3
Differentiating power of serum alanine transaminase (ALT), miRNA-125b, miRNA-124 and combined miRNA-125b and miRNA-124 for liver necroinflammation severity in patients with chronic hepatitis B (CHB). (a) Receiver operating characteristic curves and area under the curves (AUC) are presented for ALT, miRNA-125b, miRNA-124 and the combination of miRNA-125b and miRNA-124 for differentiating the severity of liver necroinflammation in patients with CHB (n = 138) from healthy controls (HCs; n = 35). (b) Moderate-to-severe necroinflammation (≥G2) in patients with normal ALT (≤50 U/L; n = 59) and (c) in patients with ALT <100 U/L (n = 80).
Clinical Microbiology and Infection  , 384.e1-384.e10DOI: ( /j.cmi )
Copyright © 2016 European Society of Clinical Microbiology and Infectious Diseases Terms and Conditions

5. Fig. 4
miRNA-125b enhanced hepatitis B virus (HBV) replication capacity in vitro. (a) HepG2.2.15 cells were transfected with step-increased levels of miRNA-125b mimic. Cells were harvested and intracellular, encapsulated HBV DNA was extracted and analysed by Southern blot analysis. (b) Supernatant hepatitis B surface antigen (HBsAg) and hepatitis B e antigen (HBeAg) levels of HepG2.2.15 cells were determined by specific ELISAs after transfection with indicated doses of miRNA-125b mimic. (c) Functional effectiveness experiment of miRNA-125b on gene enhancer of zeste homologue 2. Abbreviations: miRNA, microRNA; HBV, hepatitis B virus; HBeAg, hepatitis B e antigen; HBsAg, hepatitis B surface antigen; EZH2, enhancer of zeste homologue 2.
Clinical Microbiology and Infection  , 384.e1-384.e10DOI: ( /j.cmi )
Copyright © 2016 European Society of Clinical Microbiology and Infectious Diseases Terms and Conditions

6. FIG. S1
Serum miRNA-125b level correlates with alanine transaminase (ALT).
Clinical Microbiology and Infection  , 384.e1-384.e10DOI: ( /j.cmi )
Copyright © 2016 European Society of Clinical Microbiology and Infectious Diseases Terms and Conditions

7. FIG. S2
Serum miRNA-125b levels and liver histology of patients with chronic hepatitis B (CHB) before and after antiviral therapy (n = 29). (a) Changes in the proportion of necroinflammation (G0–4) and fibrosis (S0–4). (b) Serum miRNA-125 levels of patients with CHB before and after antiviral therapy.
Clinical Microbiology and Infection  , 384.e1-384.e10DOI: ( /j.cmi )
Copyright © 2016 European Society of Clinical Microbiology and Infectious Diseases Terms and Conditions

8. FIG. S3
HepG2.2.15 cells were transfected with miRNA control (10 nM), miRNA-1 (5 nM) and miRNA-125b (5 nM). Cells were harvested and the levels of hepatitis B virus (HBV) replicative intermediates were determined by Southern blot as previous reported prevously [9].
Clinical Microbiology and Infection  , 384.e1-384.e10DOI: ( /j.cmi )
Copyright © 2016 European Society of Clinical Microbiology and Infectious Diseases Terms and Conditions